National Guideline for Management of Hypertension for Primary Health Care Providers

Directorate of Non-Communicable Diseases Ministry of Health 2021



First Edition 2021

Electronic version is available on <u>www.health.gov.lk</u>

Directorate of Non-Communicable Diseases Ministry of Health

National guideline for management of Hypertension For Primary healthcare Providers

Published by the Directorate for Non-Communicable Diseases with the technical support by the Ceylon College of Physicians and financial support by RESOLVE

To serve as a reference to the doctors managing this common condition at primary healthcare level.

This document was reviewed by the Directorate of NCD to be in line with the National policies, strategies and regulations.

ISBN 978-624-5719-46-4

Contributors

Dr N.Maduwanthi Hettiarachchi	Specialist Physician in Internal Medicine
Dr Suranga Ravinda Manilgama	Specialist Physician in Internal Medicine
Dr Inoka Kumudini Jayasinghe	Specialist Physician in Internal Medicine
Prof Kamani Wanigasuriya	Professor of Medicine
Prof Mohamed Rifdy Mohideen	Professor and Honorary Specialist Physician Internal Medicine
Prof Nirmala Wijekoon	Professor in Pharmacology and Specialist Physician in Internal Medicine
Dr Thushara Matthias	Specialist Physician and Senior Lecturer in Internal Medicine
Dr Nilanka Perera	Specialist Physician and Senior Lecturer in Internal Medicine
Dr Indika Boteju	Specialist Physician in Internal Medicine
Prof Nishan Sudheera Kalupahana	Professor in Human Nutrition

Contributors from Directorate of NCD

Dr S.C Wickramasinghe	Specialist in Community Medicine, DDG NCD
Dr Vindya Kumarapeli	Specialist in Community Medicine, Director NCD
Dr Arundika Senarathne	Specialist in Community Medicine

Reviewers

Prof Senaka Rajapaksha	Senior Professor in Medicine, Specialist in Internal Medicine
Prof Shyamalee Samaranayaka	Professor in Family Medicine

Editorial Assistance

Dr Tasneem Naina Marikkar	Medical Officer NCD
Dr Uthpala Muhandiram	Medical Officer NCD

Table of Contents

List of Tables	vi
List of Figures	vi
List of Annexures	vi
Abbreviations	vii
Introduction	
Objectives of the Guidelines	
Chapter 1	
1.1 Definition and Grading of Hypertension	
1.2 Grading of hypertension	
1.3 Measurements of blood pressure	
1.3.1 Steps to be taken prior to the measurement of BP	
1.3.2 Steps to be followed during BP Measurement	
Chapter 2	
2.1 Diagnosis of hypertension	
2.2 Blood Pressure measurements and Recommendations	
2.3 HMOD – Hypertension Mediated Organ Damage	
2.4 Clinical assessment	
2.4.1 To look for features of HMOD	
2.4.2 To look for Secondary hypertension	
2.4.3 Cardiovascular risk stratification	9
2.5 Diagnostics	
2.6 Criteria for referral to a specialist	10
2.7 Criteria for immediate admission for specialist care	10
Chapter 3	11
3.1 Interventions for hypertension at primary care settings	11
3.2 Lifestyle interventions	11
3.3 Pharmacological interventions	12
3.4 Recommendations	12
3.4.1 Grade 1 hypertension in adults with low to moderate cardiovascular risk (<20%)	and no
CVD, DM, CKD or HMOD ,after 3-6 months of lifestyle interventions, and if BP not con	trolled,
start antihypertensive drug treatment	12
3.4.2 Grade 1 hypertension in adults with high cardiovascular risk (≥20%)	12
3.4.3 Grade 2 Hypertension (BP \geq 160/100mmHg)	12
3.5 How to approach pharmacological interventions	13
3.5.1. Stepwise approach	
3.6 Important points related to drug treatment	15
3.7 Achieving BP Targets	19
3.8 Follow up assessments	19
3.9 Emphasis on lifestyle intervention	20

3.10 Managing concomitant cardiovascular disease risk	20
3.10.1 Statin therapy	
3.10.2 Antiplatelet therapy	
3.11 Target SBP and DBP and recommended therapeutic agents	22
References	24
Annexure 1	•••••
Annexure 2	•••••
Annexure 3	•••••

List of Tables

Table 1.1 : Grading of Hypertension	2
Table 2.1 : Blood pressure measurements and recommendations	
Table 2.2 : Identifying features of HMOD in history, physical examination and laboratory finding	gs 7
Table 2.3 : Features suggestive of secondary hypertension	8
Table 3.1 : Contraindications for antihypertensive drugs	18
Table 3.2 : High, Moderate and Low intensity statin therapy	21
Table 3.3 : Target SBP and DBP and recommended therapeutic agents	22

List of Figures

Figure 1.1 : Steps to be taken before and during the measurement of blood pressure	4
Figure 3.1 : Therapeutic Option of Management of Hypertension13	3
Figure 3.2 : Stepwise approach to management of Hypertension12	7

List of Annexures

Number

- I WHO/ISH Prediction Chart
- II Anti-hypertensive drug doses and frequency
- III Desktop Summary Management of Hypertension in Primary Care

Abbreviations

ABI ABPM ACEI	Ankle Brachial Index Ambulatory Blood Pressure Monitoring Angiotensin-Converting-Enzyme Inhibitors	
AIS	Acute Ischemic Stroke	
ALT	Alanine Transaminase	
ARB	Angiotensin Receptor Blockers	
AST	Aspartate Transaminase	
BB	Beta Blockers	
BMI	Body Mass Index	
ССВ	Calcium Channel Blockers	
CVD	Cardiovascular Disease	
CKD	Chronic Kidney Disease	
CCF	Congestive Cardiac Failure	
DBP	Diastolic Blood Pressure	
DHP-CCB	Dihydropyridine (DHP) Calcium Channel Blockers	
DM	Diabetes Mellitus	
ECG	Electrocardiogram	
eGFR	estimated Glomerular Filtration Rate	
HbA1C	Glycosylated Hemoglobin	
HLC	Healthy Lifestyle Centers	
HMOD	Hypertension-Mediated Organ Damage	
ICH	Intracerebral Hemorrhage	
ISH	International Society for Hypertension	
LDL	Low Density Lipoprotein	
LVF	Left Ventricular Failure	
MRA	Mineralocorticoid Receptor Antagonist	
NCDs	Non-Communicable Diseases	
NSAID	Non-Steroidal Anti-Inflammatory Drugs	
OCP	Oral Contraceptive Pills	
OPD	Outpatient Department	
SBP	Systolic Blood Pressure	
SAH	Subarachnoid Hemorrhage	
SPC	Single Pill Combinations	
TIA	Transient Ischemic Attack	
USS	Ultrasound Scan	

Introduction

Hypertension is one of the commonest preventable causes of premature morbidity and mortality worldwide and one of the most common medical disorders, associated with increased risk of cardiovascular disease and all-cause mortality. It is the leading risk factor for the global burden of diseases.

Primary hypertension is known to affect one out of every four Sri Lankan adults and the prevalence is strongly influenced by advancing age and lifestyle factors. As the demographics of Sri Lanka is shifting towards an older population, the prevalence of hypertension and the requirement for its treatment will continue to rise. The National STEPS (2015) survey reported that 25.4% of Sri Lankan men and 26.7% of women were hypertensive and it was also found out that 31% of the population had never had their blood pressure checked.

Objectives of the Guidelines

To identify and manage patients with hypertension in primary health care institutions in a sustainable and cost-effective manner, thereby reducing the burden on the secondary/tertiary health care system in the country.

This guideline is intended for the use of Medical Officers at primary medical care institutions in Sri Lanka.

Chapter 1

1.1 Definition and Grading of Hypertension

Definition

Hypertension is defined as clinic systolic BP (SBP) \geq 140 mmHg and/or diastolic BP (DBP) \geq 90 mmHg following repeated examination

1.2 Grading of hypertension

There is a continuous association between higher BP and increased cardiovascular disease (CVD) risk. The classification is based on the BP-related CVD risk and the benefit of BP reduction as shown in clinical trials.

Category	Systolic (mmHg)		Diastolic (mmHg)
Normal BP	<130	and	<85
High-normal BP	130–139	and/or	85–89
Grade 1 hypertension	140–159	and/or	90–99
Grade 2 hypertension	≥160	and/or	≥100
Isolated systolic hypertension	≥140	and	<90

Table 1.1: Grading of Hypertension

Source: 2020 ISH Guideline

 Note: When an individual's systolic and diastolic BP falls into different categories, the patient is categorized according to the higher BP reading.

High-normal blood pressure

A systolic blood pressure 130-139mmHg and/or a diastolic blood pressure 85-89mmHg identifies people with high-normal blood pressure who would benefit from lifestyle intervention to prevent progression to established hypertension.

Assessment of cardiovascular disease risk is important in this group during evaluation to decide on optimum management and patients with high-normal blood pressure require follow-up to detect development of hypertension.

Isolated systolic hypertension

Isolated systolic hypertension is defined as elevated SBP (\geq 140mmHg) in the presence of normal/low DBP (<90mmHg). This entity is common among elderly and young individuals including children and adolescents

Primary hypertension

• Primary hypertension develops over time and a combination of risk factors may play a role.

Risk factors associated with primary hypertension are

- Male sex
- Aging
- Overweight or obesity
- Dyslipidemia
- Diabetes/insulin resistance
- Family history of early-onset hypertension
- Sedentary lifestyle
- Stress
- High sodium intake
- High alcohol intake
- Low potassium intake
- Low calcium intake

Secondary hypertension

• Secondary hypertension is defined as hypertension due to a specific cause of increased blood pressure, which may be treatable with an intervention specific to the cause.

1.3 Measurements of blood pressure

1.3.1 Steps to be taken prior to the measurement of BP:

- The patient should avoid caffeine, exercise and smoking for at least 30 min before BP measurement.
- Ensure the patient has emptied the bladder.
- Patient should be seated comfortably on a chair, feet touching the floor in a quiet environment for 5 min before beginning BP measurements.
- Remove all the clothing covering the location of cuff placement.
- Neither patient nor observer should talk during the period of rest and measurement
- Use a standard bladder cuff (12-13cm wide and 35cm long) for most patients but have wider and smaller cuffs available as the inappropriate cuff size can lead to inaccurate BP reading.
- The cuff should be positioned at the level of the heart, with the back and arm supported to avoid muscle contraction and legs should be uncrossed.
- For manual auscultatory devices, the cuff should cover 75-100% of the individual's upper arm circumference. For electronic devices, the device instructions should be followed.




Figure 1.1 : Steps to be taken before and during the measurement of blood pressure

1.3.2 Steps to be followed during BP Measurement:

- When using auscultatory methods, use phase I and V Korotkoff sound to identify SBP and DBP respectively.¹
- Two BP measurements should be recorded 1-2 minutes apart and if there is a substantial difference between the two readings, a third BP measurement should be taken. Record the average of the last two blood pressure measurements as the clinic blood pressure.
- BP should be measured in both upper arms. If there is a consistent and significant difference in BP between arms (i.e. >10 mmHg) the arm with higher BP reading should be used for subsequent measurements. If the difference of blood pressure is >20 mmHg in both arms consider further investigations.
- If the pulse is irregular, BP should be measured using direct auscultation over the brachial artery.

¹ Consider including getting the SBP with pulse or inflating initially to 180mmHg to avoid wrong SBP readings in patients with auscultatory/ silent gap

- In older people, those with DM or with symptoms of orthostatic hypotension:
 - BP should be measured in a supine or seated position
 - 1 min and 3 min after standing
 - A drop in SBP of \geq 20 mmHg or in DBP of \geq 10 mmHg within 3 minutes of standing is defined as orthostatic hypotension and is associated with an increased risk of CV events.
 - In people with a significant postural drop or symptoms of postural hypotension blood pressure target should be based on standing blood pressure.

Chapter 2

2.1 Diagnosis of hypertension

Diagnosis of hypertension and follow up is commonly based on clinic blood pressure* (BP) measurements.

The diagnosis of hypertension should not be made on a single clinic visit unless the BP is substantially elevated (\geq 180/110 mmHg) and/or there is evidence of hypertension mediated organ damage (HMOD).

Repeat BP measurements at repeat clinic visits are required to confirm the diagnosis of hypertension. The number of clinic visits and the time interval between visits are determined by the degree of BP elevation.

Patients with a substantial elevation of BP (e.g. Grade 2) require fewer clinic visits and shorter time intervals between visits (i.e. a few days or weeks) for the confirmation of the diagnosis. Conversely, repeat BP measurements extended over a few months may be required for the confirmation of diagnosis in patients with BP readings in the Grade 1 range without evidence of HMOD

*Clinic blood pressure measurement includes readings taken in OPD, medical clinics and Healthy Lifestyle Center (HLC).

2.2 Blood Pressure measurements and Recommendations

Clinic BP levels	Recommendation/action	
<120/80mmHg	Repeat BP at least annually	
120-129/80-84 mmHg	Repeat at least annually	
130-139/85-89 mmHg	Repeat BP at least annually. Consider out of clinic BP measurements to exclude masked *hypertension	
140-159/90-99mmHg	Repeat clinic BP measurements within 2 to 4 weeks to confirm the diagnosis of hypertension	
160-179/100-109 mmHg	Repeat blood pressure within two weeks to confirm the diagnosis	
≥180/110 mmHg	Confirm diagnosis if there is evidence of HMOD **(Hypertension- mediated organ damage) Repeat measurements within 1 week if there is no evidence of HMOD to confirm the diagnosis	

Table 2.1: Blood pressure measurements and recommendations

* **Masked hypertension**: Masked HT is the term used for patients with elevated BP recordings only in the out-of-clinic blood pressure (BP) recordings, while the clinic recordings are within normal range.

****HMOD:** HMOD is the damage that occurs in the brain, the heart, the kidneys, central and peripheral arteries and retina due to hypertension. HMOD is more common with longstanding hypertension and severe hypertension. However, HMOD can occur in patients with less severe hypertension.

HMOD can be reversed with the initiation of antihypertensive treatment, especially if the treatment is initiated early. However, with long-standing hypertension HMOD may become irreversible despite improved blood pressure control.

2.3 HMOD – Hypertension Mediated Organ Damage

Taking a focused history, relevant physical examinations and review available investigations would help in identifying HMOD (Refer table 2.2)

Target organ	History – current or previous	Suggestive physical examination findings	Prior investigation findings of HMOD
Brain	TIA Stroke (ICH, AIS, SAH) Dementia / memory impairment	Face, arm, leg weakness Dysphasia/dysarthria Hemiplegic gait Visual field defect	Brain imaging - old stroke
Heart and blood vessels	ACS, IHD (angina/CABG/stenting), CCF/LVF AF Aortic dissection Intermittent claudication	Pulses – irregularly irregular Low volume/absent distal pulses Apex - displaced Lung bases- fine crepitation Legs- chronic limb ischemia	ECG-AF, old MI, LVH CXR – cardiomegaly Echo- LVH ABI-<0.9
Kidneys	CKD (oedema, tiredness, Dialysis etc.)	Oedema	Proteinuria, Raised serum creatinine USS- small kidneys
Eyes	Blurred vision, visual field defects, blindness (usually late)	Advanced retinopathy (retinal hemorrhages, micro aneurysms, hard exudates, cotton wool spots and papilledema)	Fluorescein angiography

Table 2.2: Identifying features of HMOD in history, physical examination and laboratory findings

ABI-ankle brachial index, AIS- acute ischemic stroke, CCF- congestive cardiac failure, CKD-chronic kidney disease, ICH- intracerebral hemorrhage, LVF- left ventricular failure, LVH- left ventricular hypertrophy, SAH-subarachnoid hemorrhage, TIA - transient Ischemic attack, USS - ultrasound scan.

2.4 Clinical assessment

- 2.4.1 To look for features of HMOD: refer to table 2.2
- 2.4.2 To look for Secondary hypertension

2.4.2.1Evaluation of a patient for evidence of secondary hypertension

- Secondary hypertension is defined as hypertension due to a specific cause of increased blood pressure, which may be treatable with an intervention specific to the cause.
- Screening all hypertensive patients for secondary hypertension is not feasible or costeffective.
- If there are clinical features suggestive of an underlying cause for hypertension (see Table 2.3), they should be referred to a specialist for further investigations and management.

Table 2.3: Features suggestive of secondary hypertension

History	 Young age (<40 years) Acute worsening of hypertension in a previously well-controlled blood pressure History suggestive of obstructive sleep apnea (increased BMI, snoring, daytime sleepiness, gasping or choking at night, witnessed apneas during sleep) History suggestive of renal disease (hematuria, proteinuria) Features suggestive of pheochromocytoma (episodes of paroxysmal hypertension, headache, sweating and palpitations) Long term medications (NSAIDs, combined OCP, antidepressants, steroids) Recreational substances abuse
Clinical Examination	 Features of CKD (anemia, oedema) Presence of renal bruit Renal mass Delayed radial- femoral pulsation suggestive of coarctation of aorta Features of acromegaly (enlarged face, hands and feet, protrusion of jaw, large tongue) Features of Cushing syndrome (moon face, central obesity, skin atrophy, striae, and bruising; chronic steroid use)
Investigations	 Urine full report: hematuria, proteinuria Persistent hypokalemia Elevated serum creatinine

2.4.3 Cardiovascular risk stratification

Assess cardiovascular risk

- Screening for and management of modifiable CVD risk factors are recommended in adults with hypertension.
- Those with established CVD (coronary artery disease. stroke, TIA, peripheral vascular disease), CKD and DM are considered as having high CVD risk
- In the absence of above three disease conditions, the global cardiovascular risk of the individual i.e. the likelihood of a person developing a CV event (coronary heart disease, stroke or other atherosclerotic disease) over a 10-year period should be assessed using WHO/ISH chart (Annexure 1)

2.5 Diagnostics

Investigations should include basic laboratory tests and additional diagnostic tests when indicated.

Basic laboratory tests

Basic laboratory tests should be performed in all patients with hypertension.

- Fasting blood glucose
- Total cholesterol
- 12-lead ECG
- Urine protein

If facilities are available

- Urine full report or urine dipstick
- Lipid profile is preferred
- Serum creatinine and calculate eGFR
- HbAlc
- Haemoglobin and/or haematocrit
- Serum electrolytes
- ALT/AST

2.6 Criteria for referral to a specialist

- Suspected secondary hypertension based on history and examination
- HMOD: proteinuria, advanced hypertensive retinopathy, new-onset CVD, CKD etc.
- Hypertension in young (age <40 years)
- Suspected white-coat hypertension* / masked hypertension ** (when ABPM is required)
- Resistant hypertension***

***White coat hypertension:** White coat hypertension is the clinical condition when individuals who have BP readings that are consistently higher than normal only in the clinical setting, while the readings recorded outside, either by ambulatory monitoring or self-measurement at home, are normal.

****Masked hypertension**: Masked HT is the term used for patients with elevated BP recordings only in the out-of-clinic blood pressure (BP) recordings, while the clinic recordings are within normal range.

*****Resistant hypertension:** Hypertension not controlled (SBP >140 mmHg and/or DBP >90) by appropriate lifestyle measures and treatment with optimal or best-tolerated doses of three or more drugs, which should include a diuretic in patients whose adherence to therapy has been confirmed.

2.7 Criteria for immediate admission for specialist care

• Hypertensive emergency: An elevated SBP ≥180 mmHg and/or DBP ≥120 mmHg, with evidence of acute HMOD. Parenteral treatment is recommended for management of hypertensive emergencies.

Chapter 3

3.1 Interventions for hypertension at primary care settings

Treatment of hypertension includes lifestyle and pharmacological interventions. The appropriate time of initiation of treatment and type of intervention, either lifestyle modifications alone or with drug therapy, depends on the grade of HT, CVD risk level and presence of HMOD.

All those who are confirmed to have hypertension should receive appropriate lifestyle interventions.

3.2 Lifestyle interventions

- Encourage the intake of vegetables, fruits, whole grains and protein from plant sources or fish.
- Reduce intake of foods high in sugar, saturated and trans-fats.
- Individualize the eating pattern in a locally and culturally acceptable manner.
- Limit the daily salt intake to 5g (1 teaspoon). This can be achieved by avoiding addition of salt to rice and minimizing intake of high-salt food items such as soy sauce, yeast extract spreads, salt-added snacks, sausages and fast foods. When cooking dried fish it is advisable to cook it after washing several times to remove salt
- Educate patients that salt is found in many processed foods including bread. Look at the food label to identify the salt content in these foods.
- Individuals who are overweight or obese (body mass index more than or equal to 23 kgm²) to lose 5-10% of their current body weight in 3 to 6 months and maintain it thereafter.
- Minimize abdominal obesity by keeping waist circumference less than 80cm and 90cm in females and males, respectively.
- Recommend avoiding tobacco use or cessation of all forms of tobacco use.
- Recommend avoiding alcohol consumption or cessation of all forms of alcohol use
- Engage in moderate intensity aerobic exercise (e.g.: brisk walking, cycling, swimming and gardening) for 30 minutes at least on 5 days every week.
- Engage in resistance exercises on 2 to 3 days per week.

3.3 Pharmacological interventions

- Immediate initiation of pharmacological interventions is indicated for:
 - > Grade 2 hypertension
 - > Grade 1 hypertension with high cardiovascular risk (\geq 20%)
- First line medications include ACEI/ARB, DHP-CCB and thiazides/thiazide-like diuretic
- Appropriate antihypertensive drugs should be selected considering compelling indications, contraindications, conditions that require the careful use of drugs, and the presence or absence of complications
- A stepwise approach is recommended for pharmacological interventions

3.4 Recommendations

When to start pharmacological interventions

3.4.1 Grade 1 hypertension in adults with low to moderate cardiovascular risk (<20%) and has no CVD, DM, CKD or HMOD even after 3-6 months of lifestyle interventions, and if BP not controlled, start antihypertensive drug treatment

3.4.2 Grade 1 hypertension in adults with high cardiovascular risk (\geq 20%)

Upon confirmation of hypertension, initiate immediate antihypertensive drug treatment in addition to lifestyle advice if any of the following are present.

- Cardiovascular disease (CVD)
- Diabetes mellitus (DM)
- Chronic kidney disease (CKD)
- Hypertension-Mediated Organ Damage (HMOD)
- High cardiovascular risk (estimated 10-year risk ≥20% with WHO/ISH risk assessment tool)

3.4.3 Grade 2 Hypertension (BP ≥160/100mmHg)

Upon confirmation of Grade 2 hypertension initiate immediate antihypertensive drug treatment in addition to lifestyle advice.




Figure 3.1: Therapeutic Option of Management of Hypertension

3.5 How to approach pharmacological interventions

Stepwise approach to pharmacological interventions is recommended. Before moving to the next step, check adherence to lifestyle and drug treatment.

- Monotherapy is recommended as Step 1 treatment in low-risk Grade 1 hypertension, very old (>80 years), and in frail individuals
- Initial dual low-dose combination therapy is the optimal recommended treatment in other patient categories at Step 1 treatment
- **Dual full-dose combination** is recommended for Step 2 in those with inadequately controlled hypertension with Step 1 treatment
- Three-drug combination is required for patients with poorly controlled hypertension with step 2 treatment.
- When BP is poorly controlled with three-drug combination (i.e. resistant hypertension) refer to the specialist clinic for further management

3.5.1. Stepwise approach

Step 1

- Monotherapy
 - 1. Monotherapy is particularly indicated for low risk Grade 1 hypertension, patient's \geq 80 years, patients with frailty
 - 2. Monotherapy with an ACEI/ARB or a DHP-CCB* or a thiazides**/thiazide-like diuretics
 - **3.** ACEI/ARB and thiazides**/thiazide-like diuretics are preferred in post-stroke, heart failure and CCB intolerance
 - > If BP target is not achieved within 4 to 8 weeks with low dose monotherapy
 - I. Increase dose of monotherapy
 - OR
 - II. Start on dual low dose combination

• Dual low-dose combination:

Optimal step 1 treatment is dual low-dose combination (low dose generally refers to half of the maximmum recommended dose) except in those with low-risk Grade 1 hypertension, those aged \geq 80 years and those who are frail.

Desirable combinations of antihypertensive drugs include:

- Angiotensin-converting enzyme inhibitors (ACEI)/ Angiotensin receptor blockers (ARB) and Dihydropyridines Calcium Channel Blockers (DHP-CCB*)
- ARB/ACEI and thiazides**/thiazide-like divetics
- Thiazides**/thiazide-like diuretics and DHP-CCB*

*use non-DHP-CCB (e.g. diltiazem, verapamil) if DHP-CCB are not available or not tolerated **use thiazides if thiazide-like diuretics are not available

Step 2

- **Dual full-dose** (i.e. maximum tolerated therapeutic dose) **combination** with:
 - ACEI/ARB and DHP-CCB* or
 - ACEI/ARB and thiazides**/thiazide-like diuretics or
 - Thiazides**/thiazide-like diuretics and DHP-CCB*

*use non-DHP-CCB (e.g. diltiazem, verapamil) if DHP-CCB are not available or not tolerated **use thiazides if thiazide-like diuretics are not available

• Dual full-dose combination with ACEI / ARB + thiazides /thiazide-like diuretics is preferred in post-stroke, heart failure and CCB intolerance

Step 3

• Three-drug combination with:

ACEI/ARB + DHP-CCB* + thiazides** / thiazide-like diuretics

*Use non-DHP-CCB (e.g. diltiazem, verapamil) if DHP-CCB are not available or not tolerated **use thiazides if thiazide-like diuretics are not available

In all the steps, beta blockers should be considered in the regimen in those with:

- Heart failure*
- Coronary artery disease
- Atrial fibrillation
- Pregnancy or planning to become pregnant**

*the beta blockers recommended in heart failure include carvedilol, metoprolol and bisoprolol only **the beta blocker recommended in pregnancy is labetalol

3.6 Important points related to drug treatment

- Those with isolated systolic hypertension should receive the same treatment as individuals with both raised systolic and diastolic blood pressure.
- Women considering pregnancy or who are pregnant should receive treatment in line with the recommendations from a specialist clinic
- When choosing a drug, attention should be paid to the contraindications. (see Table 3.1)
- Combination of an ACEI with an ARB is not recommended.
- Using once-daily regimen which provides 24-hour blood pressure control is ideal
- Use of single pill combinations (SPCs) is preferred; use free combinations if SPCs are not available or unaffordable
- Treatment should be affordable and/or cost-effective
- Treatment should be well-tolerated




Figure 2.2 : Stepwise approach to management of Hypertension

In all the steps, **beta blockers** should be considered in the regimen in those with: - Heart failure*


- Coronary artery disease
- Atrial fibrillation
- Pregnancy or planning to become pregnant**

*the beta blockers recommended in heart failure include carvedilol, metoprolol and bisoprolol only

**the beta blocker recommended in pregnancy is labetalol

Adapted version of WHO protocol

World Health organization has recently published a protocol for primary care institution in 2021 The flow chart adapted from WHO protocol currently piloted in Kaluthara district under the "Resolve to Save Lives" project.



Depending on the success of this pilot it can be adapted after obtaining consensus from all relevant stakeholders. <u>https://apps.who.int/iris/bitstream/handle/10665/344424/9789240033986-eng.pdf</u>

> Drug doses are in Annexure 2

*Prescribe the drug according to the availability at your institution

Table 3.1:	Contraindications fo	r antihypertensive drugs
------------	----------------------	--------------------------

Drug class	Contraindications	Careful administration
ACE inhibitors	 Pregnancy Angioneurotic oedema Bilateral renal artery stenosis Hyperkalaemia 	
ARBs	PregnancyBilateral renal artery stenosisHyperkalaemia	
β-blockers	 Asthma Pulse rate less than 50 bpm Second and third-degree heart block Untreated pheochromocytoma 	 Impaired glucose tolerance Obstructive pulmonary disease Peripheral arterial disease
Dihydropyridine CCBs e.g. amlodipine, nifedipine	 Tachyarrhythmia Myocardial infarction within 1 month Significant aortic stenosis 	
Non-dihydropyridine CCBs e.g. verapamil, diltiazem	 Pulse rate less than 50 bpm Second- and third-degree heart block Heart failure 	
Thiazide diuretics	 Conditions where sodium and potassium are markedly decreased 	 Gout Pregnancy Impaired glucose tolerance
Mineralocorticoid receptor antagonist e.g. spironolactone	 Hyperkalemia eGFR <30ml/minute/1.73m² 	 Concomitant use of ACEI/ARB
Alpha blockers	History of postural hypotensionHistory of micturition syncope	

3.7 Achieving BP Targets

Recommendations

- 1 It is recommended that the first objective of treatment should be to lower BP to <140/ 90 mmHg in all patients
- 2. The systolic blood pressure target should be 120–129 mmHg in patients < 65 years.
- 3 The systolic blood pressure target should be 130–139 mmHg in patient's \geq 65 years.
- 4 In those >80 years, the systolic blood pressure target should be 130-139 mmHg provided the treatment is well tolerated
- 5 Diastolic blood pressure target should be < 80mmHg (but not less than 70 mmHg) for all hypertensive patients independent of the age, CV risk and comorbidities
- 6 Measure standing as well as sitting blood pressure in people with hypertension and
 - Diabetes mellitus or
 - Symptoms of postural hypotension or
 - Age \geq 80 years.

In people with a significant postural drop or symptoms of postural hypotension, treat to a target blood pressure based on standing blood pressure.

3.8 Follow up assessments

- The response to drug treatment and lifestyle changes should be monitored in all patients with hypertension using clinic blood pressure values every 1 to 2 months, depending on the level of BP.
- Shorter intervals between visits will be needed for symptomatic patients and those with severe hypertension (≥180/110mmHg), intolerance to antihypertensive drugs or HMOD.
- Once the BP target is reached and stable, frequency of reviewing blood pressure and follow up assessments depends on the cardiovascular risk and presence of HMOD.
- A routine follow up assessment should be done annually including assessing CV risk and HMOD.
- Investigations indicated in the follow up assessments include urinalysis, serum creatinine, serum electrolytes, blood glucose and lipid profile/total cholesterol. These could be done at the next higher level of care or through the lab networking system. ECG is required only if clinically indicated.
- When ACEI, ARB, diuretics and aldosterone antagonist are used, serum creatinine and serum electrolytes should be done 4 weeks after initiation of treatment or dose increment* if possible. Thereafter it should be repeated as clinically indicated.

*Significant rise in serum creatinine after starting / dose increment of an ACEI /ARB is suggestive of renovascular hypertension; appropriate evaluation and adjustment of treatment is advised. If the serum creatinine is found to be more than **25 % higher** than the baseline, **ACEI/ARB** should be substituted.

3.9 Emphasis on lifestyle intervention

- At each follow up visit the patients should be educated regarding the importance of lifestyle interventions.
- It is advisable to record progress of lifestyle interventions and achievement of targets.
- For further advice on lifestyle intervention please refer to National dietary and physical activity guideline for selected Non-communicable diseases: Chapter 3 for Hypertension specific diet and exercise

3.10 Managing concomitant cardiovascular disease risk

Hypertension without additional risk is not an indication for the use of statins or antiplatelet drugs.

3.10.1 Statin therapy

CV risk assessment should be carried out with the WHO/ISH risk prediction charts in hypertensive patients who are not already at high risk due to established CVD.

Recommendations

1 **Secondary prevention** in patients with established CVD*, high intensity statin therapy is recommended; refer to table 3.2

2 Statin therapy is recommended for **primary prevention** in those with,

- LDL-C \geq 190 mg/dL : high intensity statin therapy(refer to table 3.2)
- LDL 70-189 mg/dL and 10-year cardiovascular risk ≥20%: moderate to high intensity statin therapy(refer to table 3.2)

High, Moderate and Low intensity statin therapy

Statin potency category	Percentage LDL-C reduction	Type & dose of statin
High intensity	>40%	Atorvastatin 20 – 80 mg/d
		Rosuvastatin 10 – 40 mg/d
Moderate intensity	31 to 40%	Atorvastatin 10 mg/d
		Rosuvastatin 5mg/d
		Simvastatin 20 – 40 mg/d
Low intensity	20 to 30 %	Simvastatin 10 mg/d

Table 3.2: High, Moderate and Low intensity statin therapy

*CVD includes acute coronary syndromes, stable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin

Please refer to the primary care guideline on dyslipidemia for further clarification on management of dyslipidemia

3.10.2 Antiplatelet therapy

Recommendations

- 1 Antiplatelet therapy is indicated for the **secondary prevention** in patients with CVD*(Low dose Aspirin 75mg nocte)
- 2 In hypertension, antiplatelet therapy is not recommended for the primary prevention of CVD*. *CVD includes acute coronary syndromes, stable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin

3.11 Target SBP and DBP and recommended therapeutic agents

Patient category	BP target - mmHg	Drugs recommended in order of preference	
Adults 18-40 years	SBP <130 (120-129) DBP <80 (70-79)	ACEI/ARB, CCB, thiazide/thiazide-like diuretic BB, MRA, alpha blocker	
Adults 41-64 years	SBP <130 (120-129) DBP <80 (70-79)	ACEI/ARB, CCB, thiazide/thiazide-like diuretic BB, MRA, alpha blocker	
Adults 65 -80 years	*SBP <140 (130-139) DBP <80 (70-79)	CCB or a thiazide/thiazide-like diuretic preferred ACEI/ARB BB	
Adults 80 years and over	*SBP <140 (130-139) DBP <80 (70-79)	CCB or a thiazide diuretic ACEI/ARB BB	
Patients with diabetes <65 years	SBP<130 (120-129) DBP <80 (70-79)	ACEI/ARB or a CCB or thiazide/thiazide-like diuretic	
Patients with diabetes >65 years	SBP <140 (130-139) DBP <80 (70-79)	ACEI/ARB or a CCB or thiazide/thiazide-like diuretic	
Patients with diabetes with albuminuria	SBP<130 (120-129) DBP <80 (70-79)	ACEI/ARB, non-DH-CCB, thiazide/thiazide-like diuretic	
Patients with coronary heart disease <65 years	SBP <130 (120-129) DBP <80 (70-79)	BB, ACEI/ARBs DHP-CCB thiazide/thiazide-like diuretic, MRA	
Patients with coronary heart disease >65 years	SBP ≤140 (130-140) DBP <80 (70-79)	BB, ACEI /ARBs DHP-CCB	
Patients with heart failure HFrEF & HFpEF	SBP <130 (120-129) DBP <80 (70-79)	ACEI/ARB, beta blocker and thiazide/thiazide-like diuretic/loop- diuretic and/or MRA ARNI/SGLT2i if indicated	
Patients with CKD	SBP 130 DBP 80	ACEI/ARB, thiazide/thiazide-like diuretic (eGFR>30 ml/min/1.73m2) / Loop diuretic (eGFR<30	

Table 3.3: Target SBP and DBP and recommended therapeutic agents

		ml/min/1.73m2) CCB **MRA
Patients with CKD with	SBP 130	ACEI/ARB
proteinuria (≥30 mg/g)	DBP 80	Non-DHP-CCB
Patients after renal transplant	SBP<130 (120-129) DBP <80 (70-79)	ACEI/ARB
Patients with	SBP≤130 (120-130)	ACEI/ARB, CCB, thiazide/thiazide-like
cerebrovascular disease	DBP <80 (70-79)	diuretic

*If tolerated;

**caution with hyperkalemia not recommended when eGFR <30 ml/min/1.73m2

The information provided in the box can also be used when you are following up a patient referred from a higher care level

References

Ministry of Health, Nutrition and Indigenous Medicine 2015

Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775.

Ahmad M, Makati D, Akbar S. Review of and Updates on Hypertension in Obstructive Sleep Apnea. Int J Hypertens. 2017;2017:1848375. doi: 10.1155/2017/1848375.

Akpolat T, Dilek M, Aydogdu T, Adibelli Z, Erdem DG, Erdem E. Home sphygmomanometers: validation versus accuracy. Blood Press Monit 2009; 14:26–31. doi: 10.1097/MBP.0b013e3283262f31

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981–2997.doi: 10.1001/jama.288.23.2981.

Ambrosius WT, Sink KM, Foy CG., et al. SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin trials 2014 Oct; 11(5):532-46. doi: 10.1177/1740774514537404.

Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997 Apr 17;336(16):1117-24. doi: 10.1056/NEJM199704173361601.

Arima H, Christophe T., Anderson C., et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke 2010 Feb;41(2):394-6. doi: 10.1161/STROKEAHA.109.563932.

Becker, GJ, Wheeler, DC, De Zeeuw, D, et al. Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International Supplements 2012; 2(5), 337-414. https://doi.org/10.1038/kisup.2012.46

Berry JD, Dyer A, Cai X, et al. Lifetime Risks of Cardiovascular Disease. N Engl J Med. 2012;366(4):321-329. doi:10.1056/NEJMoa1012848

Boffa RJ, Constanti M, Floyd CN, Wierzbicki AS, Guideline Committee. Hypertension in adults: summary of updated NICE guidance. BMJ 2019; 367:15310. doi: 10.1136/bmj.15310.

Brewster LM, van Montfrans GA, Oehlers GP, Seedat YK. Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity. Intern Emerg Med. 2016; 11:355–374. doi: 10.1007/s11739-016-1422-x.

Bulpitt CJ, Beckett NS, Peters R., et al. Blood pressure control in the Hypertension in the Very Elderly Trial (HYVET). J Hum Hypertens, 2012;26:157-63. doi: 10.1038/jhh.2011.10.

Bundy JD, Changwei L, Stuchlik P., et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol 2017; 2: 775-81. doi: 10.1001/jamacardio.2017.1421.

Carretero OA, Oparil S. Essential Hypertension. Part I: definition and etiology. Circulation 2000 Jan 25;101(3):329-35. doi: 10.1161/01.cir.101.3.329.

Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28:1584–1590. doi: 10.1097/HJH.0b013e328339f9fa.

Dahlof B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895–906. doi: 10.1016/S0140-6736(05)67185-1.

Doreen M.R., McBrien K.A., Sapir-Pichhadze R. et al. Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology 2020 May;36(5):596-624. doi: 10.1016/j.cjca.2020.02.086.

Drawz P. Clinical Implications of Different Blood Pressure Measurement Techniques. Curr Hypertens Rep. 2017; 19(7):54. doi:10.1007/s11906-017-0751-0

Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59:1124–1131. doi: 10.1161/HYPERTENSIONAHA.112.194167.

Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007 Jan 20;369(9557):201-7. doi: 10.1016/S0140-6736(07)60108-1.

Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957–67. doi: 10.1016/S0140-6736(15)01225-8.

Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res 2017; 120: 439-48. doi.org/10.1161/ CIRCRESAHA.116.308413.

Flythe JE, Chang TI, Gallagher MP, et al.; Conference Participants. Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020 May;97(5):861-876. doi: 10.1016/j.kint.2020.01.046.

Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115mmHg, 1990-2015. JAMA 2017; 317:165–182. doi: 10.1001/jama.2016.19043.

Fried LF, Emanuele N, Zhang JH, et al.; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892–1903. doi: 10.1056/NEJMoa1303154.

Ghadieh AS, Saab B. Evidence for exercise training in the management of hypertension in adults. Can Fam Physician. 2015 Mar;61(3):233-9.

Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55:399-407.

He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and metaanalysis of randomised trials. BMJ 2013;346:f1325. Epub 2013/04/06. doi: 10.1136/bmj.f1325.

Hettiarachchi J, Mohideen MR. Hypertension in an urban community in Sri Lanka. Abstracts of the 99th anniversary academic sessions of SLMA, Colombo, March 1986.

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14;360(9349):1903-13. doi: 10.1016/s0140-6736(02)11911-8.

Ndanuko RN, Tapsell LC, Charlton KE, Neale EP, Batterham MJ. Dietary Patterns and Blood Pressure in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr 2016 Jan 15;7(1):76-89. doi: 10.3945/an.115.009753.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017; 389:37–55. doi: 10.1016/S0140-6736(16)31919-5.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses, and metaregression analyses of randomized trials. J Hypertens 2014; 32:2285–2295. doi: 10.1097/HJH.0000000000378.

Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Rezvi Sheriff MH, Matthews DR. The prevalence, predictors and associations of hypertension in Sri Lanka: a cross-sectional population based national survey. Clin Exp Hypertens. 2014; 36(7):484-91. doi: 10.3109/10641963.2013.863321.

Kumara WA, Perera T, Dissanayake M, Ranasinghe P, Constantine GR. Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country. BMC Res Notes. 2013; 6:373. Published 2013 Sep 21. doi:10.1186/1756-0500-6-373.

Jayawardana NWIA, Jayalath WATA, Madhujith WMT, et al. Aging and obesity are associated with undiagnosed hypertension in a cohort of males in the Central Province of Sri Lanka: a cross-sectional descriptive study. BMC Cardiovasc Disord. 2017; 17(1):165. Published 2017 Jun 21. doi:10.1186/s12872-017-0600-8.

Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417–2428. doi: 10.1056/NEJMoa0806182.

James P.A, Oparil S, Carter B.L. et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. JAMA 2014;311(5):507-520. doi:10.1001/jama.2013.284427

Jung MH, Kim GH, Kim JH, et al. Reliability of home blood pressure monitoring: in the context of validation and accuracy. Blood Press Monit 2015; 20:215–220. 23. doi: 10.1097/MBP.00000000000121.

Kaptoge S, Pennells L, De Bacquer D, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Heal. 2019; 7(10):e1332-e1345. doi:10.1016/S2214-109X(19)30318-3.

Kasturiratne A, Warnakulasuriya T, Pinidiyapathirage J, et al. P2-130 Epidemiology of hypertension in an urban Sri Lankan population. Journal of Epidemiology & Community Health 2011; 65:A256.

Katulanda P, Ranasinghe P, Jayawardana R, Sheriff R, Matthews DR. Metabolic syndrome among Sri Lankan adults: prevalence, patterns and correlates. Diabetol Metab Syndr. 2012; 4(1):24. Published 2012 May 31. doi:10.1186/1758-5996-4-24.

Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Rezvi Sheriff MH, Matthews DR. The prevalence, predictors and associations of hypertension in Sri Lanka: a cross-sectional population based national survey. Clin Exp Hypertens. 2014; 36(7):484-91. doi: 10.3109/10641963.2013.863321.

Katulanda P, Jayawardena Ranil, Ranasinghe P, Rezvi Sheriff MH, Matthews DR. Physical activity patterns and correlates among adults from a developing country: the Sri Lanka Diabetes and Cardiovascular Study. 2013 Sep;16(9):1684-1692. doi:10.1017/S1368980012003990.

Keith NM, Wagener HP, barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci. 1974; 268(6):336-345. doi:10.1097/00000441-197412000-00004.

Kumanan T, Guruparan M, Mohideen MR. Non-adherence of antihypertensive therapy: A serious public health issue in Sri Lanka. Journal of the Ceylon College of Physicians 2016; 47: 50-51. doi: 10.4038/jccp.v47i1.7772.

Kuncaitis J, Welch S. Evaluation of health literacy screening questions for use in the acute care setting. 2012. Accessed from https://scholarworks.gvsu.edu/ssd/2012/oral_visual/89/ on 18.11.2020.

Lawes CM, Rodgers A, Bennett DA, et al.; Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21:707–716. doi: 10.1097/00004872-200304000-00013.

Lindholm LH, Ibsen H, Dahlöf B, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359(9311):1004-10. doi: 10.1016/S0140-6736(02)08090-X.

Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD003186. doi: 10.1002/14651858.CD003186.pub3.

MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017; 6:e006986.

Martínez-González MA, Gea A, Ruiz-Canela M. The Mediterranean Diet and Cardiovascular Health. Circ Res. 2019 Mar;124(5):779-798. doi: 10.1161/CIRCRESAHA.118.313348.

Matthews KA, Katholi CR, McCreath H, et al. Blood pressure reactivity to psychological stress predicts hypertension in the CARDIA study. Circulation 2004; 110(1):74-8. doi: 10.1161/01.CIR.0000133415.37578.E4.

Matsuzaki M, Ogihara T, Umemoto S, et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29:1649–1659. doi: 10.1097/HJH.0b013e328348345d.

McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993–1004. doi: 10.1056/NEJMoa1409077.

Mohideen MR, Hettiarachchi J. The difference in blood pressures and the prevalence of hypertension in an urban and rural area in Sri Lanka. Abstracts of the 99th anniversary academic sessions of SLMA, Colombo, March 1986.

Mulè G, Calcaterra I, Nardi E, Cerasola G, Cottone S. Metabolic syndrome in hypertensive patients: An unholy alliance. World J Cardiol. 2014 Sep 26;6(9):890-907. doi: 10.4330/wjc.v6.i9.890.

Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998; 55:580–592. doi: 10.1001/archpsyc.55.7.580.

National Guideline Centre (UK). Hypertension in adults: diagnosis and management. London: National Institute for Health and Care Excellence (UK); 2019 Aug. PMID: 31577399. Accessed from https://www.nice.org.uk/guidance/ng136.

Neiman AB, Ruppar T, Ho M, et al. CDC Grand Rounds: Improving medication adherence for chronic disease management - Innovations and opportunities. Am J Transplant. 2018 Feb;18(2):514-517. doi: 10.1111/ajt.14649.

Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003;42(5):878-84. doi: 10.1161/01.HYP.0000094221.86888.AE.

Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997 Nov 4;96(9):3243-7. doi: 10.1161/01.cir.96.9.3243.

O'Donnell MJ, Chin SL, Rangarajan S, et al. INTERSTROKE Investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016; 388:761–775. doi: 10.1016/S0140-6736(16)30506-2.

O'Donnell MJ, Xavier D, Liu L, et al.; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010 Jul 10;376(9735):112-23. doi: 10.1016/S0140-6736(10)60834-3.

Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014 May 14; 35(19): 1245–1254. doi: 10.1093/eurheartj/eht534.

Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. The Lancet Public health 2017;2(2):e108-e20. doi: 10.1016/S2468-2667(17)30003-8.

Rosendorff C., Lackland D.T., Allison M., et al. Treatment of Hypertension in patients with Coronary artery disease. A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015; 65:1372-1407. doi: 10.1161/HYP.00000000000018

Senaratna CV, Perera JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: A systematic review, Sleep Medicine Reviews 2017 Aug; 34:70-81, doi: 10.1016/j.smrv.2016.07.002.

Sheriff R. Health of Sri Lankan Muslims. Some Issues to Address. AMA Azeez Oration 2005.

Standards of medical care in Diabetes – 2020: Diabetes Care 2020 Jan; 43 (Supplement 1): \$1-\$2. doi: 10.2337/dc20-Sint. Accessed from https://care.diabetesjournals.org/content/43/Supplement_1

Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ 2009 Nov 24; 339:b4567. doi: 10.1136/bmj.b4567.

Sundstrom J, Arima H, Jackson R, et al. Blood Pressure-Lowering Treatment Trialists' Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015; 162:184–191. doi: 10.7326/M14-0773.

Tan JL, Thakur K. Systolic Hypertension. [Updated 2020 Nov 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482472/

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses, and metaregression analyses of randomized trials. J Hypertens 2014; 32:2285–95. doi: 10.1097/HJH.00000000000378.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs–overview and meta-analyses. J Hypertens 2015; 33:195–211. doi: 10.1097/HJH.00000000000447.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens 2016 ;34:613–622. doi: 10.1097/HJH.00000000000881.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017; 35:922–944. doi: 10.1097/HJH.00000000001276.

Tunstall-Pedoe H, for the WHO MONICA Project. The World Health Organization MONICA Project (Monitoring Trends and Paja, k Determinants in Cardiovascular Disease): a major international collaboration. Journal of Clinical Epidemiology, 1988, 41:105–114.

Unger T, Borghi C, Charchar F, at al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020 Jun;75(6):1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026.

Van den Born BJ, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacotherapy 2019 Jan 1;5(1):37-46. doi: 10.1093/ehjcvp/pvy032.

Varon J, Marik PE. Clinical review: The management of hypertensive crises. Crit Care 2003 Oct;7(5):374-84. doi: 10.1186/cc2351.

Verdecchia P, Staessen JA, Angeli F, et al.; Cardio-Sis Investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374:525–533. doi: 10.1016/S0140-6736(09)61340-4.

Viera AJ, Neutze DM. Diagnosis of secondary hypertension: an age-based approach. Am Fam Physician 2010; 82(12):1471-1478.

Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012; 32:649–664. doi: 10.1007/BF03261919.

Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122:290–300. doi: 10.1016/j.amjmed.2008.09.038.

Xu W, Goldberg SI, Shubina M, Turchin A. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ 2015;350:h158. doi: 10.1136/bmj.h158

Zhang Y, Moran AE. Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension Among Young Adults in the United States, 1999 to 2014. Hypertension 2017 Oct;70(4):736-742. doi: 10.1161/HYPERTENSIONAHA.117.09801.


Yusuf S, Lonn E, Pais P, et al.;HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016; 374:2032–2043. doi: 10.1056/NEJMoa1600177.

Yusuf S, Teo KK, Pogue J, ,et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547–1559. doi: 10.1056/NEJMoa0801317.


Annexure 1

WHO/ISH risk prediction chart

WHO cardiovascular disease risk laboratory-based charts for Southeast Asia Indonesia, Cambodia, Lao PDR, Sri Lanka, Maldives, Myanmar, Malaysia, Philippines, Thailand, Timor-Leste, Viet Nam, Mauritius, Seychelles.



WHO cardiovascular disease risk non-laboratory-based charts for Southeast Asia Indonesia, Cambodia, Lao PDR, Sri Lanka, Maldives, Myanmar, Malaysia, Philippines, Thailand, Timor-Leste, Viet Nam, Mauritius, Seychelles. Risk Level 0



WHO cardiovascular disease risk non-laboratory-based charts Southeast Asia

Indonesia, Cambodia, Lao PDR, Sri Lanka, Maldives, Myanmar, Malaysia, Philippines, Thailand, Timor-Leste, Viet Nam, Mauritius, Seychelles.


- Estimate the 10 year cardiovascular risk as follows using laboratory based charts;
 - Step 1 Select the appropriate chart depending on the presence or absence of diabetes
 - Step 2 Select male or female tables
 - Step 3 Select smoker or non-smoker boxes
 - Step 4 Select age group box (if age is 54; select 50-54, if age is 55; select 55-59)

Step 5 – Within this box find the nearest cell where the individual's systolic blood pressure (mmHg) and the total blood cholesterol level (mmol/l) cross. The colour and the number of this cell determines the 10 year cardiovascular risk.

Estimate the 10 year cardiovascular risk as follows using non laboratory based charts;

- Step 1 Select male or female tables
- Step 2 Select smoker or non-smoker boxes
- Step 3 Select age group box

Step 4 – Within this box find the nearest cell where the individual's systolic blood pressure (mmHg) and the Body Mass Index (kg/m²) value cross. The colour and the number of this cell determines the 10 year cardiovascular risk.



```
< 5%
```

5 % - < 10 %

10 % - < 20 %

20 % - < 30 %

 \geq 30 %

Annexure 2 Antihypertension Drug doses and frequency

Drug class	Drugs	Starting dose	Maximum therapeutic dose	
ACEI	Captopril Enalapril Imidapril Lisinopril Perindopril Ramipril	12.5mg BD 5mg OD 5mg OD 10mg OD 5mg OD 2.5mg OD	25mg to 50 mg to 75mg BD 10mg to 20mg OD 20mg OD 80mg OD 10mg OD 10mg OD	
ARB	Losartan	50mg OD	100mg OD	
	Candesartan	8mg OD	32mg OD	
	Irbesartan	150mg OD	300mg OD	
	Olmesartan	10mg OD	40mg OD	
	Telmisartan	20mg OD	80mg OD	
	Valsartan	80mg OD	320mg OD	
DHP-CCB	Amlodipine	5mg OD	10mg OD	
	Nifedipine extended-release	20mg OD	20mgBD to 40mgBD	
Non-DHP-CCB	Diltiazem	30mg TDS	60mg TDS	
	Diltiazem extended-release	90mg BD	180 mg BD	
	Verapamil	40mg TDS	80 mg TDS	
	Verapamil extended-release	240mg OD	240mg BD	
Thiazides/thiazide like diuretics	Hydrochlorothiazide Chlorthalidone Indapamide Indapamide extended-release	12.5mg OD 25mg OD 2.5mg OD 1.5mg OD	25mg OD 50mg OD 2.5mgOD 1.5mg OD	
Beta blockers	Atenolol	25mg OD	50mg OD	
	Bisoprolol	5mg OD	20mg OD	
	Carvedilol	12.5mg OD	50mg OD	
	Labetalol	100mg BD	400mg BD	
	Metoprolol	100mg OD	200mg BD	
Aldosterone antagonists Recommended for treating resistant hypertension	Spironolactone	12.5mg OD	50mg OD	
Alpha blockers	Prazosin	0.5mg BD/TDS	6mg TDS	
	Prazosin extended-release	2.5mg OD	20mg OD	

Annexure 3

Desktop Summary – Management of Hypertension in Primary Care

Measure blood pressure on two occasions

Check for presence of hypertension-mediated organ damage and secondary hypertension in history, examination and previous investigations Assessment of Cardiovascular risk

	<120/80	120-129 / 80-84	130-139 / 85-89	140-159 / 90-99	160-179 /100-109	>180/110 with no HMOD\$	>180/110 with HMOD
Repeat measurement	1 year	1 year	1 year	2 to 4 weeks	within 2 weeks	within 1 week	No
*Lifestyle advice (LSA)	Yes	Yes	Yes	Yes	Yes	Yes	Yes
**Investigate	No	No	No	Yes	Yes	Yes	Yes
Start drugs	No	No	No except in High CV risk#	Yes, if BP remains	Yes, if BP remains ↑	Yes, if BP remains ↑	Yes, immediately

∞Specialist referral

- Suspected secondary hypertension based on history and examination
- HMOD: proteinuria, advanced hypertensive retinopathy, new-onset CVD, CKD etc.
- Hypertension in young (age <40 years)
- Suspected white-coat hypertension / masked • hypertension (when ABPM is required)
- Resistant hypertension
- Pregnancy

*Lifestyle advice

• Healthy diet

**Basic Investigations

- Fasting blood glucose
- Physical activity
- Cessation of tobacco and alcohol
- Optimise weight
- Total cholesterol

1.11

- 12- lead ECG
- Urine protein

#High CV risk

- CV risk >20%
- Existing CVD,
 - DM, CKD
- HMOD

(if facilities available) Urine full report or urine dipstick

****Extended Investigations**

Lipid profile

•

•

•

- Serum creatinine and eGFR
- Glycated HbA1c •
- Haemoglobin and/or haematocrit
- Serum electrolytes
- ALT/AST

\$HMOD (Hypertension

- mediated organ damage)
- Heart (ACS, LVH, HF)
- Brain (Stroke, TIA)
- Kidneys (Proteinuria, CKD)
- Eyes (Adv retinopathy)
- BV (PVD)

E1 (1)	End to the second state of the second	1
Effective of	lual combinations	Indications
ACEI or ARB	CCB	DM
ACEI or ARB	Thiazides or Thiazide-	HF, Stroke,
	like	DM
ACEI or ARB	Carvedilol, Bisoprolol	HF
CCB	Thiazides or Thiazide-	Stroke
	like	
DHP-CCB or	Betablockers	IHD
ACEi or ARB	Carvedilol, Bisoprolol,	
ACEi or ARB	Carvedilol,Bisoprolol, Atenolol	

Antinypertensive medications					
Class of drugs	Starting dose	Max dose			
Diuretics (HCT)	12.5mg OD	25 mg OD			
ACEI or ARBS	5mg OD	10-20 mg OD			
(Enalapril or Losartan)	50mg OD	100 mg OD			
Calcium channel	5mg OD	10mg OD			
blockers (Amlodipine)					
Nifedipine SR	20mg OD	20mg BD-40mg BD			
Betablockers	25mg OD	50mg OD			
(Atenolol)					
olockers (Amlodipine) lifedipine SR Betablockers	20mg OD	20mg BD-40mg BD			

nortonolivo m

